Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons-Reference-Cited by-同舟云学术

Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons

Published:1993-01 Issue:2 Volume:45 Page:331-337
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Taudou Georges,Portemer Christiane,Jaxel Christine,Duguet Michel

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference37 articles.

1. DNA topoisomerases;Gellert;Annu Rev Biochem,1981

2. Recent studies of DNA topoisomerases;Wang;Biochim Biophys Acta,1987

3. Proteinassociated DNA breaks in cells treated by adriamycin or ellipticin;Ross;Biochim Biophys Acta,1978

4. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9 acridinylamino)- methanesulfon-m-anisidide;Nelson,1984

5. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II;Chen;J Biol Chem,1984

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets;Journal of Medicinal Chemistry;2019-10-08

2. Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant;Drug Metabolism and Disposition;2016-04-06

3. Phase I and Pharmacokinetic Study of Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors;Journal of Clinical Oncology;2004-03-01

4. Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer;European Journal of Cancer;2003-02

5. Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer;Investigational New Drugs;2003